Hesham Gamal El Dine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hesham Gamal El Dine has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abeer Ramadan
Molecular Genetics and Enzymology Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
1 shared publication - Alshaimaa Rezk Lotfy Rezk Alnaggar
Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt
1 shared publication Amany H. Abdelrahman
Clinical and Chemical Pathology Department, Medical Division, National Research Centre, Cairo, Egypt
1 shared publication- Asmaa Ali
Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
1 shared publication Asmaa Mohammed
Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication- Eman A. Elghoroury
Clinical & Chemical Pathology Department, National Research Centre, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 31 March 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (1) , 129-137
Pro-apoptotic Bax mRNA expression: A novel predictor for systemic lupus erythematosus disease flare-up
Objectives: In this study, we aimed to better understand the expression of pro-apoptotic Bad and Bax in the pathogenesis of systemic lupus erythematosus (SLE) and their relationship with the disease activity. Patients and methods: Between June 2019 and January 2021, a total of 60 female patients with SLE (median age 29 years; IQR, 25.0-32.0) and 60 age- and sex-matched healthy female controls (median age: 30 years; IQR, 24.0-32.0) were included. The Bax and Bad messenger ribonucleic acid (mRNA) expression was measured by real-time polymerase chain reaction. Results: The expression of Bax and Bad was significantly lower in SLE group than the control group. The median value of mRNA expression of Bax and Bad was 0.72 and 0.84, respectively versus 0.76 and 0.89 in the control group. The median value of (Bax*Bad)/β-actin index was 17.8 in the SLE group and 19.64 in the control group. The expression of both Bax, Bad and (Bax*Bad)/β-actin index had a good significant diagnostic utility (area under the curve [AUC]= 0.64, 0.70, and 0.65, respectively). The Bax mRNA expression showed a significant upregulation with disease flare-up. The efficacy of Bax mRNA expression in predicting SLE flare-up was good (AUC= 73%). In the regression model, the probability of flare-up reached 100%, with increasing Bax/β-actin as well, and the likelihood of flare-up increased 10,314 times with every unit increase of Bax/β-actin mRNA expression. Conclusion: Deregulation of the mRNA expression of Bax may have a role in the susceptibility to SLE and may be associated with disease flare. A better understanding of the expression of these pro-apoptotic molecules may carry a great potential for the development of specific effective therapies.
- 31 March 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (1) , 129-137
Open AccessPro-apoptotic Bax mRNA expression: A novel predictor for systemic lupus erythematosus disease flare-up
Objectives: In this study, we aimed to better understand the expression of pro-apoptotic Bad and Bax in the pathogenesis of systemic lupus erythematosus (SLE) and their relationship with the disease activity. Patients and methods: Between June 2019 and January 2021, a total of 60 female patients with SLE (median age 29 years; IQR, 25.0-32.0) and 60 age- and sex-matched healthy female controls (median age: 30 years; IQR, 24.0-32.0) were included. The Bax and Bad messenger ribonucleic acid (mRNA) expression was measured by real-time polymerase chain reaction. Results: The expression of Bax and Bad was significantly lower in SLE group than the control group. The median value of mRNA expression of Bax and Bad was 0.72 and 0.84, respectively versus 0.76 and 0.89 in the control group. The median value of (Bax*Bad)/β-actin index was 17.8 in the SLE group and 19.64 in the control group. The expression of both Bax, Bad and (Bax*Bad)/β-actin index had a good significant diagnostic utility (area under the curve [AUC]= 0.64, 0.70, and 0.65, respectively). The Bax mRNA expression showed a significant upregulation with disease flare-up. The efficacy of Bax mRNA expression in predicting SLE flare-up was good (AUC= 73%). In the regression model, the probability of flare-up reached 100%, with increasing Bax/β-actin as well, and the likelihood of flare-up increased 10,314 times with every unit increase of Bax/β-actin mRNA expression. Conclusion: Deregulation of the mRNA expression of Bax may have a role in the susceptibility to SLE and may be associated with disease flare. A better understanding of the expression of these pro-apoptotic molecules may carry a great potential for the development of specific effective therapies.
- 1 August 2018
- Published by Elsevier in Clinical Breast Cancer
- Vol. 18 (4) , e721-e726
Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer
- 1 August 2018
- Published by Elsevier in Clinical Breast Cancer
- Vol. 18 (4) , e721-e726
Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer